In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type 1 selected

Type

Guidance programme 5 selected

Guidance programme

Showing 1 to 10 of 26

TitleConsultationTypeConsultation end date
Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer ID6734Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Talazoparib with enzalutamide for treating hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation ID6460Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy ID6645Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Tislelizumab with platinum-based chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer at high risk of recurrence ID6708Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Draft guidanceTechnology appraisal guidance
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps [ID6379]Draft guidanceTechnology appraisal guidance
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]Draft guidanceTechnology appraisal guidance
Pembrolizumab with chemotherapy with or without bevacizumab for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Draft guidanceTechnology appraisal guidance
Nemolizumab for treating prurigo nodularis [ID6451]Final draft guidanceTechnology appraisal guidance
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All